Source:
Source:
Source:Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Stem Cell Therapy
$80 Million in Grants, Money for Viacyte and Blue-Ribbon Report on California Stem Cell Agency
Posted: December 9, 2012 at 8:00 am
Directors of the California stem cell
agency are expected to give away $80 million next week to 20
fortunate researchers in addition to exploring a “commercialization
and industry engagement plan.”
The subjects are on tap for the Dec. 12 meeting in Los Angeles of the governing board of the $3 billion
research effort.
research effort.
The $80 million grant round is aimed at
“career development of physician scientists working in
translational stem cell research.”
“career development of physician scientists working in
translational stem cell research.”
“This award will fund promising
physician scientists in the critical early stages of their careers as
independent investigators and faculty members establishing their own
laboratories and programs.”
Summaries of the grant reviewers
comments and application scores should be available sometime this
week. The bare-bones agenda lacked elaboration on the
commercialization plan.
comments and application scores should be available sometime this
week. The bare-bones agenda lacked elaboration on the
commercialization plan.
Directors are additionally scheduled to
hear a presentation on the blue-ribbon report by the Institute of
Medicine for which the agency is paying $700,000. The report has been
17 months in the making and is scheduled to be released this
Thursday.
hear a presentation on the blue-ribbon report by the Institute of
Medicine for which the agency is paying $700,000. The report has been
17 months in the making and is scheduled to be released this
Thursday.
Other interesting matters are on the
table, although the agency has yet to produce background material
laying out any details. The subjects include:
table, although the agency has yet to produce background material
laying out any details. The subjects include:
- More money – no amount yet specified
– for Viacyte, Inc, of San Diego, which has received more than $36
million from CIRM. - An update of the agency's response to
the only performance audit conducted at the agency. The audit
identified 27 areas where improvement is needed, but the governing
board has not discussed the results publicly since they were
disclosed last May. - Approval of the concept plan for
another round of basic biology grants and adoption of conflict of
interest code changes.
Interested parties will be able to take part at the meeting location in Los Angeles and teleconference locations in La Jolla, Oakland and UCSF. If you are interested in
the teleconference locations, you will need to contact the agency for more specific directions than are provided on the agenda.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on $80 Million in Grants, Money for Viacyte and Blue-Ribbon Report on California Stem Cell Agency
Extra, Extra! CIRM Staffers Blog the World Stem Cell Summit
Posted: December 9, 2012 at 8:00 am
Years ago, I worked with an editor who
used to advise his lagging scribes to put their noses in their
typewriters and peck.
Well, the folks at the California stem cell agency have their
noses in what passes today for typewriters and are pecking away
furiously. Their subject is the World Stem Cell Summit, which has
received only slight coverage in the mainstream media.
noses in what passes today for typewriters and are pecking away
furiously. Their subject is the World Stem Cell Summit, which has
received only slight coverage in the mainstream media.
Today, the stem “cellists” from San
Francisco's King Street filed -- on the agency's blog -- three fulsome
items on doings at the summit, which is taking place in West Palm
Beach, Fla. Yesterday they filed four. Photos and charts were
included. More coverage is expected tomorrow.
Francisco's King Street filed -- on the agency's blog -- three fulsome
items on doings at the summit, which is taking place in West Palm
Beach, Fla. Yesterday they filed four. Photos and charts were
included. More coverage is expected tomorrow.
 |
| CIRM staffers blogging the World Stem Cell Summit covered UC Davis researcher Paul Knoepfler discussing patient advocacy and its role in funding stem cell research. |
The CIRM writers are doing double-duty
in at least one case. Geoff Lomax, the agency's senior officer for
its standards group, is additionally speaking on a panel at the session. A
handful of other CIRM officials are also appearing at the conference,
which ends tomorrow.
The primary purpose, we presume, of
sending state employees across the country is to gather the latest
information on stem cell science and issues and to make contacts. It
is a bit of a bonus for the public to have the CIRM attendees also
file stories on the sessions.
sending state employees across the country is to gather the latest
information on stem cell science and issues and to make contacts. It
is a bit of a bonus for the public to have the CIRM attendees also
file stories on the sessions.
A couple of the items caught my
attention. One dealt with patient advocates and their role in
energizing and helping to drive funding for research. Another item
discussed what appear to be growing issues with dubious stem cell treatments and the damage they can do to the field in general.
attention. One dealt with patient advocates and their role in
energizing and helping to drive funding for research. Another item
discussed what appear to be growing issues with dubious stem cell treatments and the damage they can do to the field in general.
Lomax summarized the signs of a stem
cell scam like this:
cell scam like this:
- “Claims of miracle cures for
diseases - “Single treatments or cells that
can treat any type of disease - “Lack of objective information,
evidence (such as published medical reports) that a treatment is
effective - “Treatment by a doctor who is
not trained or certified to treat the specific disease - “No system exists to collect
information and follow up with patients”
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Extra, Extra! CIRM Staffers Blog the World Stem Cell Summit
Update on Move To Curb Researcher Appeals at California Stem Cell Agency
Posted: December 9, 2012 at 8:00 am
Directors of the $3 billion California
stem cell agency are still mulling details of changes in their
free-wheeling and sometimes emotional appeals process for grant applications
that are rejected by the agency's reviewers.
A special task force of directors met last week
for the second time to discuss the likely alterations. Kevin McCormack, spokesman for the agency, said
the group made no decisions. Another meeting will be held later at a
date to be determined. The task force's recommendations will then go
before the full board, probably in late January.
for the second time to discuss the likely alterations. Kevin McCormack, spokesman for the agency, said
the group made no decisions. Another meeting will be held later at a
date to be determined. The task force's recommendations will then go
before the full board, probably in late January.
McCormack said members of the panel
have asked for “more details regarding the process that would be
employed if the appeals and extraordinary petition processes were
merged.”
have asked for “more details regarding the process that would be
employed if the appeals and extraordinary petition processes were
merged.”
The agency has an odd, bifurcated
appeals process. Early in its existence, the agency said appeals of
reviewer decisions could be based only on conflicts of interest.
However, researchers have a right under state law to speak to the
governing board in public on any issue whatsoever. As some
researchers began to use that avenue to ask for reconsideration of
their applications, the CIRM board created what it called
“extraordinary petitions” in an effort to control the process and
limit appeals. Both the “appeals” and “extraordinary petitions”
are, in fact, appeals but on different grounds and employing different
mechanisms.
appeals process. Early in its existence, the agency said appeals of
reviewer decisions could be based only on conflicts of interest.
However, researchers have a right under state law to speak to the
governing board in public on any issue whatsoever. As some
researchers began to use that avenue to ask for reconsideration of
their applications, the CIRM board created what it called
“extraordinary petitions” in an effort to control the process and
limit appeals. Both the “appeals” and “extraordinary petitions”
are, in fact, appeals but on different grounds and employing different
mechanisms.
The task force was created in September
after directors complained about “arm-twisting” and “emotionally charged presentations” in connection with a record number of
appeals earlier this year.
after directors complained about “arm-twisting” and “emotionally charged presentations” in connection with a record number of
appeals earlier this year.
Here is a link to an item about the task force's first meeting. Here is a link to an agency summary of the task force's deliberations prior to last week's meeting. The
transcript of the session should be available on the CIRM web site
within the next two weeks. It will be found under the meetings
section of the web and then under the heading for the task force's
November session.
transcript of the session should be available on the CIRM web site
within the next two weeks. It will be found under the meetings
section of the web and then under the heading for the task force's
November session.
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/Hkq7zcXyMsQ/update-on-move-to-curb-researcher.html
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Update on Move To Curb Researcher Appeals at California Stem Cell Agency
Precision StemCell’s Neural Reprogrammed Stem Cell Therapy Yields Better-Than-Expected Results for ALS Patients
Posted: December 5, 2012 at 2:44 pm
GULF SHORES, Ala., Dec. 4, 2012 /PRNewswire/ --More than 75 percent of amyotrophic lateral sclerosis (ALS) patients who received neural reprogrammed stem cell therapy have shown a positive response to the procedure. The groundbreaking technique was introduced to the United States this year by Precision StemCell (http://www.precisionstemcell.com), an outpatient imaging and image-guided treatment facility located in Gulf Shores, Ala.
The procedure is performed by Dr. Jason R. Williams, a board-certified radiologist with extensive training in image-guided procedures. Under his care, 14 out of 18 patients diagnosed with ALS, also known as Lou Gehrig's disease, have shown signs of recovery.
"The improvements are mild, with patients reporting improved movement, breathing and speech, but we still have a long way to go," Dr. Williams stated. "Only time will tell how this therapy will affect the patients' long-term prognosis."
In Precision StemCell's neural reprogrammed stem cell therapy, fat-derived stem cells are injected into the spine of the patient. Dr. Williams uses a drug called selegeline, which has been shown to be a pre-inducer of adipose-derived stem cells into neural-like cells. Dr. Williams contends that the therapy is probably one of the largest advances seen in ALS therapy. "Before we started this therapy, I would have been happy just to see the progression of the disease halted, but to see some actual improvement, that was just shocking," he said
The first patient treated with the technique was Frank Orgel who continues to see improvement since his first treatment seven months ago. Eight years ago, Orgel's quality of life had declined to the point that he could not move his left arm or leg, walk or even stand on his own. The therapy has allowed Orgel to stand without assistance, and he continues to work with a physical therapist to regain the ability to walk. Another patient, Dexter Johnson, previously walked with a cane. After the treatment, Johnson has been able to walk without his cane for the majority of the time and he has been able to walk at a much faster pace.
The Precision StemCell center focuses on advanced imaging techniques, which include a 3T Open MRI, a low-dose 64-Slice CT Scanner, ultrasound and fluoroscopy, also known as real-time x-ray. The center is headed by Dr. Williams, who specializes in image-guided procedures, had already been performing magnetic resonance imaging (MRI), computed tomography (CT), ultrasound and fluoroscopy-guided stem cell injections for joint and orthopedic conditions.
In addition to their current work on advanced stem cell harvesting and processing with image-guided stem cell injections, Precision StemCell staff are planning to conduct further research so as to develop even more advanced techniques such as adding gene therapy to the current neural reprogramming platform. "Our therapy techniques not only hold promise for ALS patients, but also for people with other neural-related conditions such as Parkinson's and spinal cord injuries," said Dr. Williams. "There are several candidate genes that we plan to add to the adipose-derived stem cells and study in the mouse model. Though we are happy with our initial progress, our goal is to develop an effective cure."
About Precision StemCell
Located in Gulf Shores, Alabama, Precision StemCell conducts stem cell procedures using advanced imaging techniques, which include an Open 3T MRI, a low-dose 64-Slice CT scanner, ultrasound, and real time x-ray (fluoroscopy). Headed by Jason Williams, MD, a board-certified radiologist with extensive training in image-guided procedures, the facility performs advanced stem cell harvesting and processing with image-guided stem cell injections.
Contact:
Posted in Stem Cell Therapy
Comments Off on Precision StemCell’s Neural Reprogrammed Stem Cell Therapy Yields Better-Than-Expected Results for ALS Patients
Precision StemCell's Neural Reprogrammed Stem Cell Therapy Yields Better-Than-Expected Results for ALS Patients
Posted: December 5, 2012 at 6:40 am
GULF SHORES, Ala., Dec. 4, 2012 /PRNewswire/ --More than 75 percent of amyotrophic lateral sclerosis (ALS) patients who received neural reprogrammed stem cell therapy have shown a positive response to the procedure. The groundbreaking technique was introduced to the United States this year by Precision StemCell (http://www.precisionstemcell.com), an outpatient imaging and image-guided treatment facility located in Gulf Shores, Ala.
The procedure is performed by Dr. Jason R. Williams, a board-certified radiologist with extensive training in image-guided procedures. Under his care, 14 out of 18 patients diagnosed with ALS, also known as Lou Gehrig's disease, have shown signs of recovery.
"The improvements are mild, with patients reporting improved movement, breathing and speech, but we still have a long way to go," Dr. Williams stated. "Only time will tell how this therapy will affect the patients' long-term prognosis."
In Precision StemCell's neural reprogrammed stem cell therapy, fat-derived stem cells are injected into the spine of the patient. Dr. Williams uses a drug called selegeline, which has been shown to be a pre-inducer of adipose-derived stem cells into neural-like cells. Dr. Williams contends that the therapy is probably one of the largest advances seen in ALS therapy. "Before we started this therapy, I would have been happy just to see the progression of the disease halted, but to see some actual improvement, that was just shocking," he said
The first patient treated with the technique was Frank Orgel who continues to see improvement since his first treatment seven months ago. Eight years ago, Orgel's quality of life had declined to the point that he could not move his left arm or leg, walk or even stand on his own. The therapy has allowed Orgel to stand without assistance, and he continues to work with a physical therapist to regain the ability to walk. Another patient, Dexter Johnson, previously walked with a cane. After the treatment, Johnson has been able to walk without his cane for the majority of the time and he has been able to walk at a much faster pace.
The Precision StemCell center focuses on advanced imaging techniques, which include a 3T Open MRI, a low-dose 64-Slice CT Scanner, ultrasound and fluoroscopy, also known as real-time x-ray. The center is headed by Dr. Williams, who specializes in image-guided procedures, had already been performing magnetic resonance imaging (MRI), computed tomography (CT), ultrasound and fluoroscopy-guided stem cell injections for joint and orthopedic conditions.
In addition to their current work on advanced stem cell harvesting and processing with image-guided stem cell injections, Precision StemCell staff are planning to conduct further research so as to develop even more advanced techniques such as adding gene therapy to the current neural reprogramming platform. "Our therapy techniques not only hold promise for ALS patients, but also for people with other neural-related conditions such as Parkinson's and spinal cord injuries," said Dr. Williams. "There are several candidate genes that we plan to add to the adipose-derived stem cells and study in the mouse model. Though we are happy with our initial progress, our goal is to develop an effective cure."
About Precision StemCell
Located in Gulf Shores, Alabama, Precision StemCell conducts stem cell procedures using advanced imaging techniques, which include an Open 3T MRI, a low-dose 64-Slice CT scanner, ultrasound, and real time x-ray (fluoroscopy). Headed by Jason Williams, MD, a board-certified radiologist with extensive training in image-guided procedures, the facility performs advanced stem cell harvesting and processing with image-guided stem cell injections.
Contact:
Go here to see the original:
Precision StemCell's Neural Reprogrammed Stem Cell Therapy Yields Better-Than-Expected Results for ALS Patients
Posted in Stem Cell Therapy
Comments Off on Precision StemCell's Neural Reprogrammed Stem Cell Therapy Yields Better-Than-Expected Results for ALS Patients
World Stem Cell Summit Fuels Economy
Posted: December 4, 2012 at 6:40 am
Posted by Juan Carlos Fanjul/CBS 12 News
WEST PALM BEACH, Fla-- It may look like boring exhibits and the usual convention type crowds, but in this hall life-saving science is being talked about and big money will eventually make it into the local economy.
"Probably injecting over a million dollars in the local economy and it's a showcase for Palm Beach County," said event organizer Bernard Siegel.
Siegel says over 1,200 scientists from more than 40 countries are at the Palm Beach County Convention Center this week for the 8th annual World Stem Cell Summit.
With the opening of Max Planck this week and the continued growth of Scripps in northern Palm Beach County and Torrey Pines in Saint Lucie County, Siegel says this convention means a coming of age for the region's biotech sector.
"This is considered the largest meeting in the country and we have the top scientists," he added.
Claudia Zylberberg owns AKRON Biotech, a Boca Raton-based supplier of raw materials for stem cell therapy she started just a few years ago.
"I realized early on there was a lot of potential for growth and this turned out the right place to be," she said.
Doctor Joshua Hare leads the Interdisciplinary Stem Cell Institute for the University of Miami and says he's noticed growth too.
"We don't have the critical mass of Baltimore or Boston and we would like to see that, but you are seeing the seeds of that right now," he said. World Stem Cell Summit Fuels Economy
Posted in Cell Therapy, Stem Cell Therapy
Comments Off on World Stem Cell Summit Fuels Economy
World stem cell event opens in West Palm Beach
Posted: December 4, 2012 at 6:40 am
We have permission to take others off the website, http://www.worldstemcellsummit.com/featured-speakers
World Stem Cell Summit organizer Bernie Siegel has joined forces with scientists from the University of Miami to host the 1,000 attendees from 34 countries expected at the summit in West Palm Beach this week.
Each have made discoveries in stem-cell research that could make a difference for those suffering from diabetes and heart disease.
Dr. Joshua Hare, a cardiologist at UM's Miller School of Medicine, has been a pioneer the use of stem cell therapy to repair damaged hearts. Recently, he completed a clinical trial where scarring was reduced by 33 percent in patients who had previous heart attacks.
"The No. 1 reason for heart failure is because of cardiac scarring. If you can remove it and replace with new tissue, that's very exciting," he said.
Dr. Camillo Ricordi, director of UM's Diabetes Research Institute, developed an experimental procedure that has improved blood glucose control and the quality of life of some Type 1 diabetics. But the procedure involves organ donors.
Ultimately, he's seeking a cure that involves "replacing cells in Type 1 diabetics with insulin-producing cells that are in our own body."
"I definitely think the cure is within our reach. We've had so much progress within the last three years," said Ricordi, who posts updates on his research on facebook.com/DiabetesResearch.org.
Other top speakers at the summit include:
Dr. George Daley, director of the Stem Cell Transplantation Program, HHMI/Children's Hospital in Boston where he specializing in research and drug development for those with leukemia and genetic blood disorders.
Posted in Cell Therapy, Stem Cell Therapy
Comments Off on World stem cell event opens in West Palm Beach
Stem Cell Board Members Lubin and Sheehy Honored
Posted: December 2, 2012 at 7:59 am
A couple of members of the governing
board of the $3 billion California stem cell agency were honored for
their work this month.
 |
| Jeff Sheehy UCSF Photo |
One is Jeff Sheehy, a UCSF
communications manager and nationally known HIV/AIDS advocate, who
has served on the CIRM board since its inception. He was named by POZ
magazine as one of the top 100 “soldiers” in the fight against
HIV/AIDS.
communications manager and nationally known HIV/AIDS advocate, who
has served on the CIRM board since its inception. He was named by POZ
magazine as one of the top 100 “soldiers” in the fight against
HIV/AIDS.
CIRM's Amy Adams filed an item on
Sheehy on the agency's blog yesterday. She said,
Sheehy on the agency's blog yesterday. She said,
“Jeff once told me
that when he joined CIRM’s board eight years ago, he didn’t see a
role for stem cells in an HIV/AIDS treatment. Now, CIRM has committed
$40 million toward HIV/AIDS projects and two teams of researchers
from City
of Hope and UCLA are
working toward clinical trials.”
Sheehy was also invited to the White
House to commemorate World AIDs day Dec. 1.
House to commemorate World AIDs day Dec. 1.
 |
| Bert Lubin Childrens Hospital Photo |
Also honored was Bert Lubin, CEO of
Childrens Hospital in Oakland, where he has worked since 1973, a
remarkable achievement in today's world of transitory employment. The
San Francisco Business Times named Lubin as the “most admiredCEO” in the San Francisco Bay Area. The newspaper said that since
he took charge at Childrens in 2009,
Childrens Hospital in Oakland, where he has worked since 1973, a
remarkable achievement in today's world of transitory employment. The
San Francisco Business Times named Lubin as the “most admiredCEO” in the San Francisco Bay Area. The newspaper said that since
he took charge at Childrens in 2009,
“He recruited a new senior management
team, chopped away at the pediatric hospital’s operating deficit
and worked to heal relationships with the local community and
governmental and political leaders that were deeply frayed...”
On a personal note, a friend who has
long volunteered at Childrens gives him high marks as well, citing
several encounters where he exceeded the usual CEO effort.
long volunteered at Childrens gives him high marks as well, citing
several encounters where he exceeded the usual CEO effort.
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/9b9s3mW2ebM/stem-cell-board-members-lubin-and.html
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Stem Cell Board Members Lubin and Sheehy Honored
Knoepfler Award Update: More than a Baker’s Dozen Nominated
Posted: December 2, 2012 at 7:59 am
As of this week, 14 persons have been
recommended for the Knoepfler “Stem Cell Person of the Year”
Award.
The total was reported by Paul
Knoepfler, the UC Davis stem cell scientist and blogger, who is
putting up $1,000 for the winner of the honor.
Knoepfler, the UC Davis stem cell scientist and blogger, who is
putting up $1,000 for the winner of the honor.
Knoepfler announced his award plans earlier this month, declaring that he wanted to recognize scientists or others who “truly made a difference” in the stem
field. Risk-taking is one important criteria.
field. Risk-taking is one important criteria.
Knoepfler said,
“It’s something that I’m hoping I
can do every year. It would also be a reward for risk taking,
creativity and be breaking with tradition and be something new in
that regard.”
The award has drawn some modest
attention outside of Knoepfler's blog. A few days after he introduced
the award on his blog, UC Davis decided to put out a press release and video on it. The California Stem Cell Report followed with an item. Then CIRM blogged it as well.
attention outside of Knoepfler's blog. A few days after he introduced
the award on his blog, UC Davis decided to put out a press release and video on it. The California Stem Cell Report followed with an item. Then CIRM blogged it as well.
So far we have not detected any stories
about the award in the mainstream media, but things could change.
about the award in the mainstream media, but things could change.
Deadline for entries is Dec. 17.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Knoepfler Award Update: More than a Baker’s Dozen Nominated
Diane Winokur, Veteran ALS Patient Advocate, Named to California Stem Cell Agency Board
Posted: December 2, 2012 at 7:59 am
Longtime ALS patient advocate Diane
Winokur of San Francisco, who has lost two sons to the disease, has
been appointed to the governing board of the $3 billion California
stem cell agency.
She fills the vacancy left by David
Serrano Sewell, who resigned from the 29-member panel earlier this
year after serving since the agency's inception. CIRM has 10 patient advocates
on its board.
Serrano Sewell, who resigned from the 29-member panel earlier this
year after serving since the agency's inception. CIRM has 10 patient advocates
on its board.
 |
| Diane Winokur Photo -- Legal Momentum |
Winokur is well-known in ALS circles.
She sat for five years on the governing board of the national ALS
advocacy group and currently serves on the board for the California
state group, the Golden West chapter. She also served for six years on the board of
trustees for the Sanford- Burnham Institute in La Jolla, which has received $37 million from the stem cell agency. She left Sanford in 2011.
She sat for five years on the governing board of the national ALS
advocacy group and currently serves on the board for the California
state group, the Golden West chapter. She also served for six years on the board of
trustees for the Sanford- Burnham Institute in La Jolla, which has received $37 million from the stem cell agency. She left Sanford in 2011.
Last summer Winokur appeared before the
CIRM board to successfully seek approval of an $18 million ALS grant
that was rejected by the agency's reviewers. Researcher Clive
Svendsen of Cedars-Sinai in Los Angeles appealed the denial to the
full board and was supported in emotional testimony by other patient
advocates as well, including persons with the affliction.(See here for video of some of the testimony.)
CIRM board to successfully seek approval of an $18 million ALS grant
that was rejected by the agency's reviewers. Researcher Clive
Svendsen of Cedars-Sinai in Los Angeles appealed the denial to the
full board and was supported in emotional testimony by other patient
advocates as well, including persons with the affliction.(See here for video of some of the testimony.)
The agency has awarded about $30.6
million, including the Svendsen grant, for research directly related
to ALS.
million, including the Svendsen grant, for research directly related
to ALS.
Golden
West issued a press release Nov. 21, lauding the Winokur appointment
by California Lt. Gov. Gavin Newsom. The release quoted Lucie Bruijn,
chief scientist of The ALS Association, as saying,
West issued a press release Nov. 21, lauding the Winokur appointment
by California Lt. Gov. Gavin Newsom. The release quoted Lucie Bruijn,
chief scientist of The ALS Association, as saying,
"Her
contributions have been invaluable and she will be a tremendous asset
in moving the ALS research field forward through CIRM
funding."
The stem cell agency posted a blog item
on Winokur's appointment in addition to a press release. CIRM
Chairman J.T. Thomas said,
on Winokur's appointment in addition to a press release. CIRM
Chairman J.T. Thomas said,
“Her knowledge, expertise and
leadership will be a tremendous addition to the ICOC (the stem cell
agency governing board) and help guide us in our work.”
Patient advocate Don Reed of Fremont,
Ca., described Winokur in a 2008 blog item as “small, elegant, full
of energy, an exclamation point of a person.”
Ca., described Winokur in a 2008 blog item as “small, elegant, full
of energy, an exclamation point of a person.”
(Editor's note: Based on information from CIRM and Golden West, an earlier version of this item incorrectly stated that Winokur is a current member of the Sanford-Burnham board.
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/dITcyP7WJbs/diane-winokur-veteran-als-patient.html
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Diane Winokur, Veteran ALS Patient Advocate, Named to California Stem Cell Agency Board
